BOARD OF DIRECTORS

The Treatment Research Institute is governed by a nine-member Board of experts in substance abuse and related fields.

Carolyn Asbury, ScMPH, PhD, Board Chair, is Senior Consultant at the Dana Foundation, where she supports clinical research in immunology and in neuroscience, including addiction. She is also Senior Fellow of the University of Pennsylvania’s Leonard Davis Institute where she conducts research on orphan medical drugs. Dr. Asbury is formerly of The Robert Wood Johnson Foundation and a former Director of The Pew Charitable Trusts’ Health and Human Services Program.

Mathea Falco, Esq. is President of Drug Strategies, a nonprofit research institute that identifies effective approaches to substance abuse. The author of The Making of a Drug-Free America: Programs That Work, Ms. Falco comments frequently on drug policy in the media and in public speeches across the country. Until 1993, she was Director of Health Policy, Department of Public Health, Cornell University Medical College in New York City. From 1977 to 1981, Ms. Falco was Assistant Secretary of State for International Narcotics Matters. In earlier positions, she served as Chief Counsel and Staff Director of the U.S. Senate Judiciary Committee, Juvenile Delinquency Subcommittee, and as Special Assistant to the President of the Drug Abuse Council. Ms. Falco has been a member of the Board of Overseers of Harvard University, a Trustee of Radcliffe College, and the Chair of the Visiting Committee on Harvard University Health Services. She also has served on the national boards of Girl Scouts, USA; Big Brothers of America; the International Women's Health Coalition, the Ploughshares Fund; and the National Council on Crime and Delinquency. Ms. Falco is a graduate of Radcliffe College and Yale Law School.

Herbert D. Kleber, MD is Professor of Psychiatry and Director of the Division on Substance Abuse at the Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute. Until 2001, he was Executive Vice-President and Medical Director of the National Center on Addiction and Substance Abuse (CASA), a policy center he and Joseph Califano founded in 1992. He previously served for more than two years as the Deputy Director for Demand Reduction at the Office of National Drug Control Policy in the White House. He has received numerous awards, is listed as one of the "Best Doctors in America" and "Best Doctors in New York," was elected in 1996 to The Institute of Medicine of the National Academy of Science, and serves on the National Advisory Council to the National Institute on Drug Abuse.

Kenneth A. Lynch, CPA, MT is Assistant Vice President for Financial Reporting and Risk Management at South Jersey Industries, Inc. He has 20 years of experience performing assurance services and advising companies on complex financial issues. Formerly a Senior Manager in the Entrepreneurial Services Group of Ernst and Young LLP, Ken has served a wide range of clients from closely held, emerging growth companies to multi-national, publicly traded entities. These clients have primarily been in the manufacturing, retail, distribution, software, service and technology industries. Ken has assisted numerous clients as they enter into significant transactions such as mergers, acquisitions and public offerings.

A. Thomas McLellan, PhD, is a psychologist, Professor of Psychiatry at the University of Pennsylvania, and co-founder and Chief Executive Officer of TRI. He is best known for his leading role in creation of the Addiction Severity Index and the Treatment Services Review, two of the most widely used instruments in the field of substance abuse. Among McLellan's many honors and awards are the Life Achievement Award of the American Society of Addiction Medicine in 2003 and the 2002 award for Distinguished Contribution in Addiction Medicine from the Swedish Medical Association.

Charles P. O’Brien, MD, PhD is Chief of Psychiatry at the Philadelphia VA Medical Center, and Vice-Chair of Psychiatry at the University of Pennsylvania where he is also Director of the Center for Studies of Addiction. O’Brien was elected to the Institute of Medicine of the National Academy of Sciences in 1991, and has received numerous national research awards as well as an honorary Doctorate from the University of Bordeaux in 1994 and the Nathan P. Eddy award for research on addiction from the College on Problems of Drug Dependence. O’Brien’s research focus is on discovery of changes to the central nervous system involved in relapse, new medications, behavioral treatments, and instruments for measuring the severity of addictive disorders. He is past President of both the American College of Neuropsychopharmacology and the Association for Research in Nervous and Mental Disease.

Stephen J. Pasierb, MEd, is President and CEO of the Partnership for a Drug-Free America. He joined the Partnership in 1993, was named to the Board of Directors in 2000, and became president in October 2001. Under Steve’s leadership, the Partnership coordinates combined substance abuse education campaigns which garner annual media donations totaling $400 million. Operationally, the Partnership has produced five consecutive years of double digit revenue growth, leveraging every donated dollar into 38 dollars of program services. The organization has continued its unprecedented record of effectiveness, as confirmed via research, most recently with a program addressing Ecstasy that helped drive down teen usage of this illicit drug by 50 percent, as well as launched an innovative education initiative on addiction intervention and treatment (Hope, Help & HealingTM™) while supporting parents as they strive to raise healthy, drug-free kids (Partnering with FamiliesTM™). In 2004, the Partnership was one of 13 organizations world-wide to receive the Discovery Health Medical Honors award for its extraordinary contributions to world health. The Partnership has been rated 4 stars — the highest rating — from Charity Navigator for efficient use of donor funding. And, the New York Times has called the Partnership, "One of the most effective drug prevention organizations in the U.S."

C. Richard Peterson is the CEO of Reflective Learning. He was previously CEO of Penn Capital Insurance Company, and before that, from 1994 to 1998, was Vice Chairman of Minet Group, PLC and CEO of its North American retail and wholesale operations. Minet Group is an insurance brokerage firm based in London. Prior to Minet, he was Executive Vice President of Sedgwick Group, an insurance brokerage firm also based in London before its acquisition by Marsh and McLennan. Mr. Peterson was CEO of Sedgwick’s New York office. While with the Sedgwick Group, Mr. Peterson served a term of eight years on the executive committee of the National Association of Insurance Brokers and was its President in 1990-1991. Mr. Peterson also serves on the Board of Trustees of the Eisenhower Fellowships and was Treasurer of the Eisenhower Foundation from 2001-2005. He also serves on the Board of Directors of Pennsylvania Lumbermens Mutual, a property/casualty insurance company based in Philadelphia. Mr. Peterson attended Colby College (BA) and the University of Pennsylvania (BS), and he attended management development programs at Harvard Business School (PMD) and Oxford University (AMP).

George E. Woody, MD is a Professor in the Department of Psychiatry at the University of Pennsylvania with 35 years of specialized research on treatment efficacy in substance abuse. Among his notable achievements are founding member of the Board of Addiction Psychiatry of the American Psychiatric Association, two-time member of the Board of Directors of the College on Problems of Drug Dependence, and Life Fellow of the American Psychiatric Association. He is currently Director of the Delaware Valley Node of the NIDA-funded Clinical Trials Network.